| Propanc Biopharma, Inc. |
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 |
| Balance Sheet Date | | | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2014-Mar-31 | 2013-Dec-31 |
| Fiscal Period | | | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 |
| Operating Cash Flow | | | (27,186$) | (136,196$) | (6,271$) | (235,515$) | (259,966$) | (102,810$) | (238,885$) | (333,457$) | (177,973$) | (192,736$) | (225,227$) | (509,315$) | (410,998$) | (314,213$) | (224,335$) | (486,758$) | (236,287$) | (468,002$) | (261,026$) | (179,949$) | (499,658$) | (207,054$) | (416,546$) | (726,331$) | (266,232$) | (737,019$) | (637,590$) | (419,196$) | (447,560$) | (658,759$) | (285,658$) | (785,668$) | | | | | | | | | | | 172,185$ | 99,811$ | 364,109$ | (35,847$) | (26,636$) |
| Investing Cash Flow | | | | | | | | | | | | | | | | | | | | | | | | | | | 0$ | (1,212$) | | | | | | | | | | | | 0$ | 3$ | (679$) | (4,667$) | (918$) | 0$ | 0$ | 0$ | 0$ | 0$ |
| Financing Cash Flow | | | 7,756$ | 187,485$ | 79,816$ | 215,699$ | 250,974$ | 66,644$ | 273,929$ | 350,347$ | 100,000$ | 269,500$ | 250,000$ | 494,219$ | 374,286$ | 327,000$ | 354,500$ | 435,000$ | 250,000$ | 450,000$ | 200,000$ | 158,044$ | 424,990$ | 335,250$ | 265,000$ | 865,000$ | 198,401$ | 694,267$ | 745,473$ | 480,419$ | 503,233$ | 619,255$ | 380,000$ | 894,000$ | | | | | | | | | | | | | | 45,886$ | (22,359$) |
| End Cash Position | | | | | | | | | | | | 93,241$ | 24,476$ | 19,396$ | 4,067$ | 133,885$ | 73,616$ | 45,817$ | 2,255$ | 14,439$ | | | 67,007$ | | | | | | | | | | | | | | | | | | | | | | 14,588$ | 4,513$ | 87,799$ | 40$ | 736$ |
| Exchange Rate Effect | | | (19,242$) | (15,162$) | (68,180$) | 7,999$ | 23,855$ | (29,262$) | 29,981$ | (20,312$) | (5,221$) | (7,999$) | (19,693$) | 30,425$ | (93,106$) | 47,482$ | (102,366$) | 95,320$ | (25,897$) | 11,198$ | 31,051$ | 6,116$ | 114,718$ | (113,261$) | 67,444$ | (44,940$) | (36,985$) | 26,636$ | (20,597$) | (42,230$) | (45,048$) | (63,696$) | | | | | | | | | | | | | | | | | |
| Dividends Paid | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |